We and others have previously shown that the manipulation of BCR-ABL1 catalytic activity modulates its intracellular localization, thereby transforming the culprit of CML into a pro-apoptotic protein that selectively kills leukemic cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.